

10/573090

IAP9 Res'd PCT/PTO 15 MAR 2006

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  PTO Form 1449	Attorney Docket No. 056291-5241	Serial No. Unassigned
	Applicants Christopher Thomas HALSALL	
	Filing Date March 15, 2006	Group Unassigned 1624

## U.S. PATENT DOCUMENTS


*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation	
							YES	NO
TNT	/	WO 03/082290 A	Oct. 9, 2003		WIPO		X	
TNT	/	WO 03/082831 A	Oct. 9, 2003		WIPO		X	
TNT	/	WO 02/092578 A	Nov. 21, 2002		WIPO		X	
TNT	/	WO 00/31048 A	June 2, 2000		WIPO		X	
TNT	/	WO 03/040108 A	May 15, 2003		WIPO		X	
TNT	/	WO 01/94341 A	Dec. 13, 2001		WIPO		X	
TNT	/	WO 00/55141 A	Sept. 21, 2000		WIPO		X	
TNT	/	WO 01/32651 A	May 10, 2001		WIPO		X	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TNT	TSOU H-R, et al., "6-Substituted-4-(3-Bromophenylamino) Quina Zolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity", 2001, Journal of Medicinal Chemistry, US, pp 2719-2734.
TNT	HENNEQUIN, Laurent F., et al., "Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors", Journal of Medicinal Chemistry, vol. 45, no. 6, pp. 1300-1312, 2002.
TNT	SMALL, Jeff B., et al., "Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor...", Journal of Medicinal Chemistry, vol. 43, no. 7, pp. 1380-1397, 2000.
TNT	GAUL, Micheal, et al., "Discovery and Biological Evaluation of Potent Dual ErbB-2/Egfr Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines", Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 637-640, 2003.

Examiner 	Date Considered 2-10-09
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	